Vertex EVP sells 2,633 company shares

Vertex Pharmaceuticals executive Duncan McKechnie sold 2,633 shares of common stock in an open-market transaction.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Duncan McKechnie sold 2,633 shares of common stock in an open-market transaction. The sale occurred on March 11, 2026, at an average price of $498.42 per share. After the sale, he directly held 12,489 Vertex shares.

The transaction was made under a company-approved Rule 10b5-1 trading plan that Mr. McKechnie entered into on November 25, 2025, indicating the sale was pre-scheduled rather than opportunistic.

Insider Trade Summary 10b5-1

Net Seller: 2,633 shares

Net Sell 1 txn

Insider McKechnie Duncan

Role EVP, Chief Commercial Officer

Sold 2,633 shs ($1.31M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,633	$498.42	$1.31M

Holdings After Transaction: Common Stock — 12,489 shares (Direct)

Footnotes (1)

F1. Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex Pharmaceuticals (VRTX) report for Duncan McKechnie?

Vertex Pharmaceuticals reported that EVP and Chief Commercial Officer Duncan McKechnie sold 2,633 shares of common stock. The open-market sale occurred at an average price of $498.42 per share and was disclosed in a Form 4 insider trading report.

At what price did Duncan McKechnie sell his VRTX shares and how many remain?

Duncan McKechnie sold 2,633 Vertex shares at an average price of $498.42 each. Following this open-market transaction, he directly holds 12,489 shares of Vertex Pharmaceuticals common stock, as reflected in the reported post-transaction ownership.

Was Duncan McKechnie’s VRTX stock sale under a Rule 10b5-1 trading plan?

Yes. The sale was made under a company-approved Rule 10b5-1 trading plan entered on November 25, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of transaction timing as an indicator of management’s short-term outlook.

What role does Duncan McKechnie hold at Vertex Pharmaceuticals (VRTX)?

Duncan McKechnie serves as Executive Vice President and Chief Commercial Officer at Vertex Pharmaceuticals. His Form 4 filing reports personal open-market sales of company common stock and discloses his remaining direct ownership following the transaction.

How many VRTX shares did Duncan McKechnie sell according to the latest Form 4?

According to the Form 4, Duncan McKechnie sold 2,633 shares of Vertex Pharmaceuticals common stock. The transaction is classified as an open-market sale and reduced his direct holdings to 12,489 shares after completion of the trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/13/2026 - 04:11 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKechnie Duncan

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/11/2026		S⁽¹⁾		2,633	D	$498.42	12,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Omar White, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR